PreHevbrio global net revenue increased 52% quarter-over-quarter from Q2 to Q3 2023
Continued execution across earlier-stage pipeline, including:
Initiation of Phase 2b study of VBI-1901 in.
The study author discusses the impact of findings showing MASH resolution without worsening fibrosis is a surrogate endpoint for 15-year bariatric surgery survival.
Reductions in key non-invasive tests of liver inflammation and fibrosis support previously demonstrated fibrosis improvements across compensated cirrhotic patients at week 24 A.